Beijing Biostar Pharmaceuticals (HKG:2563) made a stellar trading debut in Hong Kong on Thursday, Oct. 31.
The biotech firm closed at HK$20.8 per share, up 30% from its IPO price of HK$16, after an over 34% gain at the opening bell.
The oncology-focused biopharmaceutical company raised HK$196 million in net proceeds from its initial public offering after pricing the shares at the lower end of the indicative range.
The drugmaker issued 14,588,000 shares at HK$16 apiece, the bottom of its guidance of as high as HK$22 each, according to a Thursday disclosure.
The deal's public offering portion was 21.45 times oversubscribed, prompting the company to reallocate 291,800 shares from the international offering, which was not fully subscribed.
A total of 1,750,600 shares were issued under the public offer, while 12,837,400 shares were issued under the international offer.
IPO proceeds will be used for clinical trials, production capacity expansion, and marketing efforts.
Price (HKD): $18607.93, Change: $-100, Percent Change: -0.56%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。